Amylyx Pharmaceuticals (AMLX) Profit After Tax: 2021-2025
Historic Profit After Tax for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$34.4 million.
- Amylyx Pharmaceuticals' Profit After Tax rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 42.47%. This contributed to the annual value of -$301.7 million for FY2024, which is 712.42% down from last year.
- Amylyx Pharmaceuticals' Profit After Tax amounted to -$34.4 million in Q3 2025, which was up 17.03% from -$41.4 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Profit After Tax registered a high of $22.1 million during Q2 2023, and its lowest value of -$118.8 million during Q1 2024.
- In the last 3 years, Amylyx Pharmaceuticals' Profit After Tax had a median value of -$35.9 million in 2025 and averaged -$33.1 million.
- In the last 5 years, Amylyx Pharmaceuticals' Profit After Tax surged by 140.83% in 2023 and then tumbled by 7,652.00% in 2024.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Profit After Tax stood at -$28.3 million in 2021, then slumped by 50.66% to -$42.7 million in 2022, then surged by 111.08% to $4.7 million in 2023, then plummeted by 893.62% to -$37.5 million in 2024, then surged by 52.70% to -$34.4 million in 2025.
- Its Profit After Tax was -$34.4 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$35.9 million in Q1 2025.